Publications by authors named "Rong-Wei Xie"
Article Synopsis
- The study focuses on spontaneous rupture of hepatocellular carcinoma (HCC), examining how patients are categorized in different staging systems after this life-threatening event.
- A retrospective analysis of 1952 patients showed that those with rupture while in early BCLC stages had better overall survival rates compared to those in advanced stage C, despite similar recurrence-free survival.
- The findings indicate that patients who suffer a tumor rupture while in BCLC stage A or B should not be automatically re-staged to C, as their prognosis is significantly better.
Background: Adjuvant therapy may improve survival of patients with hepatocellular carcinoma (HCC) after curative resection. This study compared safety and efficacy outcomes between patients at high risk of recurrence who received different types of adjuvant therapy or no such therapy after hepatic resection for HCC.
Methods: Recurrence-free survival (RFS), overall survival, and adverse events were compared among patients who received adjuvant immune checkpoint inhibitors (ICIs) alone, ICIs with tyrosine kinase inhibitors (TKIs), or no adjuvant therapy between 13 March 2019 and 19 March 2022.